Algeta schedules first quarter 2012 results presentation, webcast and conference call
(Thomson Reuters ONE) -
Oslo, Norway, 23 April 2012 - Algeta ASA (OSE: ALGETA), a company focused on the
development of novel targeted cancer therapeutics, will announce its first
quarter 2012 results on Thursday, 3 May 2012. A presentation by Algeta's senior
management team to investors, analysts and the press will take place in Oslo at
10:00 CET.
The presentation will also be webcast live and can be accessed at
www.algeta.com/webcast where questions can also be submitted during the
presentation.
The presentation will take place at 10:00 CET at:
Shippingklubben
Haakon VIIs gate 1
0161 Oslo
Norway.
Algeta's senior management will also host an international conference call at
14:30 CET/08:30 Eastern Time (US) (details below).
To participate in the conference call, please dial the appropriate number below
five minutes prior to the call:
USA: +1 866 5088 015
UK: +44 203 147 4601
Norway: +47 21 01 09 30
Sweden: +46 850 559 840
Switzerland: +41 225 802 964
For other countries, please see the attached list of access numbers.
Participant pin code: 903804#
To access the replay, please dial:
USA: +1 866 3056 292
UK: +44 207 750 99 28
Norway: +47 21 01 09 26
Sweden: +46 850 626 949
Conference reference: 270516#
A replay version of the conference call will also be available at
www.algeta.com.
The results report and the presentation will be available at www.algeta.com in
the Investors section from 07:00 CET.
###
For further information, please contact
Mike Booth +47 2202 4510
Communications & Corporate Affairs ir(at)algeta.com
International media enquiries: +44 207 638 9571
Mark Swallow mark.swallow(at)citigatedr.co.uk
Citigate Dewe Rogerson
US investor enquiries: +1 646 378 2928
Jessica Lloyd jlloyd(at)troutgroup.com
The Trout Group
About Algeta
Algeta is a company focused on developing novel targeted therapies for patients
with cancer based on its alpha-pharmaceutical platform.
Algeta's lead product Alpharadin (radium-223 chloride) is in development as a
potential new treatment for cancer patients with bone metastases. It is in pre-
registration for castration-resistant prostate cancer (CRPC) patients with bone
metastases, and filings are expected mid 2012 in the USA and Europe; Alpharadin
has Fast Track designation for this indication in the USA.
Alpharadin is also under clinical investigation in breast cancer patients with
bone metastases and in combination with docetaxel chemotherapy in CPRC patients
with bone metastases.
Alpharadin is being developed and will be commercialized, pending approval,
under a global agreement with Bayer Pharma AG. Algeta and Bayer will co-promote
Alpharadin in the United States, while Bayer will promote Alpharadin in the rest
of the world.
Algeta is also exploring the potential of Targeted Thorium Conjugates (TTCs),
which are based on conjugating the alpha-emitter thorium-227 to targeting
molecules, as a basis of a future pipeline of tumor-targeting alpha-
pharmaceutical candidates.
The Company is headquartered in Oslo, Norway, and is listed on the Oslo Stock
Exchange (Ticker: ALGETA).
Alpharadin and Algeta are trademarks of Algeta ASA.
Forward-looking Statements
This news release contains certain forward-looking statements based on
uncertainty, since they relate to events and depend on circumstances that will
occur in the future and which, by their nature, will have an impact on results
of operations and the financial condition of Algeta. Such forward-looking
statements reflect our current views and are based on the information currently
available to Algeta. Algeta cannot give any assurance to the correctness of such
statements. There are a number of factors that could cause actual results and
developments to differ materially from those expressed or implied by these
forward-looking statements. These factors include, among other things,
unforeseen delays in the timing of expected regulatory filings, risks or
uncertainties associated with the success of future clinical trials,
collaborations with other companies in the development of targeting molecules
and alpha particle payloads, the ability to identify and hire a sufficient
number of qualified employees for the US field force, growth management, general
economic and business conditions and the pricing environment, the impact of
competition, the ability to successfully commercialize Alpharadin and our other
products, the risk that costs associated with the co-promotion of Alpharadin may
be greater than anticipated, the risk that research & development will not yield
new products that achieve commercial success, manufacturing capacity, the risk
of non-approval of patents not yet granted, risks in obtaining regulatory
approvals for Alpharadin and our other products and difficulties of obtaining
relevant governmental approvals for new products, and the other risks and
uncertainties described in our annual report.
This information is subject of the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.
International access numbers:
http://hugin.info/134655/R/1604524/507728.pdf
Press release:
http://hugin.info/134655/R/1604524/507727.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Algeta ASA via Thomson Reuters ONE
[HUG#1604524]
Unternehmensinformation / Kurzprofil:
Datum: 23.04.2012 - 08:00 Uhr
Sprache: Deutsch
News-ID 137744
Anzahl Zeichen: 6845
contact information:
Town:
Oslo
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 142 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Algeta schedules first quarter 2012 results presentation, webcast and conference call"
steht unter der journalistisch-redaktionellen Verantwortung von
Algeta ASA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
